LONDON — The benefit of mineralocorticoid receptor antagonists (MRAs) for the treatment of patients with heart failure and mildly reduced or preserved ejection fraction has finally been established in ...

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

Simultaneous or rapid initiation of evidence-based therapies significantly improves quality of life and outcomes in patients with heart failure with moderately reduced or preserved ejection fraction, ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), and the Japanese Heart Failure Society (JHFS) announced today a new ...

Lower risk for composite of death from cardiovascular causes or worsening heart failure seen with tirzepatide versus placebo. (HealthDay News) — For patients with heart failure with preserved ejection ...

Panelists discuss how heart failure classification involves HFrEF vs HFpEF distinctions and staging systems (A through D), with the greatest prevention opportunities existing in early stages A and B, ...

GLP-1s improved outcomes in patients with heart failure with preserved ejection fraction, with or without obesity, but those ...

Smith and colleagues [1] addressed the problem of determining the prognosis of heart failure patients with preserved ejection fraction (EF) and published their results in the Journal of the American ...